AV 5080
Alternative Names: AV-5080Latest Information Update: 02 Nov 2021
At a glance
- Originator Ministry of Health of the Russian Federation; Viriom
- Developer Viriom
- Class Antivirals; Small molecules
- Mechanism of Action Neuraminidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Influenza virus infections
Most Recent Events
- 26 Oct 2021 Preclinical trials in Influenza virus infections in Russia (PO) (NCT05093998)
- 26 Oct 2021 Viriom plans a phase III trial for Influenza virus infections in Russia (PO, Capsule) in Jan 2022 (NCT05093998)
- 24 Mar 2020 Viriom, China center for disease control and prevention and Ministry of Health of Russian Federation agree to determine the antiviral activity of AV 5080 for COVID-19 infections